Debarkin is used to treat generalized or partial epilepsy, especially the following seizure types: absence seizure, myoclonic seizure, flaccid seizure and mixed seizure, partial epilepsy: simple or complex seizure; Secondary generalized seizures; Special type syndrome (West, Lennox-Gastaut).
Nervous system disorder: during the treatment of this product, a few patients appear lethargy or stupor, which leads to transient coma (encephalopathy). During treatment, they may appear alone or simultaneously with epilepsy. When the dose is reduced or stopped, these symptoms will be alleviated. These cases are usually found after combined treatment, especially when the dose of phenobarbital or valproic acid suddenly increases. Gastrointestinal dysfunction (nausea and stomachache) often occurs at the initial stage of treatment, but the symptoms usually disappear within a few days without stopping treatment. Short-term and/or dose-related adverse reactions are often reported: alopecia, mild postural tremor and drowsiness. It is reported that simple fibrinogen reduction or prolonged bleeding time is usually not accompanied by clinical signs, and mostly occurs in large doses.
Oxcarbazepine is suitable for adults with epilepsy and children over 5 years old, and is used to treat primary generalized tonic-clonic seizures and partial seizures with or without secondary generalized seizures. The most common adverse reactions of oxcarbazepine are drowsiness, headache, dizziness, diplopia, nausea, vomiting and fatigue, which will occur in patients over 10%.